Welcome to the ChatIBD Beta
Hello, and welcome to ChatIBD. Our mission is to create a trusted companion for clinicians navigating the ever-growing number of clinical guidelines in inflammatory bowel disease (IBD). We hope you’ll find this tool useful, and we look forward to improving it together with your feedback.
What is ChatIBD?
ChatIBD is an AI-powered assistant that provides quick, guideline-based answers to practical questions in IBD care. It does not replace clinical judgment, but helps clinicians cut through lengthy documents and access key recommendations in seconds.
AI guidance, grounded in trusted data
ChatIBD uses large language models (LLMs) to understand and answer clinical questions. Like many tools in medicine, these models are not absolute. The same question asked twice may yield slightly different answers.
To make sure key information is always reliable, ChatIBD can reference a structured dosing database maintained by ourselves (which we curate mainly by reading the EMA's Product Information Publications). When drug dosing is discussed, this verified source appears in a highlighted blue card, alongside the guideline-based analysis. This makes it easy to confirm accurate, consistent information at a glance.
Here's an example of what the drug dosing card looks like:
Notes
- Monitor FBC, LFTs, and lipids.
- Induction may be extended to 16 weeks if response at week 8 is inadequate.
- Discontinue if no response by week 16.
- *10 mg orally twice daily may be considered if response decreases on 5 mg twice daily
- *10 mg twice daily for maintenance treatment is not recommended in patients with known venous thromboembolism, major adverse cardiovascular events and malignancy risk factors, unless there is no suitable alternative treatment available.
- *10 mg twice daily for maintenance should be used for the shortest duration possible.
- Contraindicated in pregnancy.
In practice, ChatIBD combines two strengths: the flexibility of AI to handle complex, open-ended queries, and the certainty of fixed clinical data where precision matters most.
Who is ChatIBD for?
ChatIBD is designed for healthcare professionals who care for people with inflammatory bowel disease. It aims to support consultant gastroenterologists and IBD specialists who want rapid access to up-to-date recommendations, IBD nurses and allied health professionals who need quick summaries to guide care, and trainees or junior doctors who are still building familiarity with complex guidelines. Researchers and educators may also find it useful as a fast reference tool to complement teaching and study.
ChatIBD is not intended for patients or the general public. It complements, but does not replace clinical expertise.
What ChatIBD Can Do
Concise guideline-based answers
ChatIBD provides concise answers grounded in international and national IBD guidelines. Direct source references are provided for easy verification.
Reliable drug dosing information
When questions involve drug dosing, ChatIBD calls a structured dosing database. These answers are shown in a highlighted blue card, ensuring consistent, accurate dosing information alongside the guideline-based context.
Localised recommendations
Where possible, ChatIBD will attempt to tailor its answers to your country’s guidelines and provide a comparison with others. If you’d like additional guidelines included, email us at contact@chatibd.com. You can see the list of currently included guidelines in the knowledge base link in the sidebar.
Deep Research
With deep research mode, ChatIBD can search the web for relevant information when answers to questions aren’t available from the guidelines. This feature is accessible from the Knowledge Base menu once you’re logged in.
What ChatIBD Cannot Do
ChatIBD cannot replace clinical judgment or the responsibility that rests with healthcare professionals in caring for patients. Like all AI systems, it is not infallible, and occasional errors are possible. It is not designed to provide personalised medical advice or to substitute for reading full guidelines or primary evidence where necessary.
Instead, ChatIBD is a copilot that helps clinicians save time, stay up to date, and deliver more consistent care, while ensuring that decision-making remains firmly in human hands.
Safety and Monitoring
We recognise that safety and trust are essential. To measure accuracy properly, we first need to understand how ChatIBD is used in the real world i.e. the questions that clinicians actually ask. To support this, we have built a continuous safety monitoring system.
Every response can be flagged if you believe it is inaccurate or unsafe. All flagged responses are reviewed by our team, and once we have collected sufficient data, we will share benchmarking results on ChatIBD's real world performance here on this blog.
This approach lets us improve ChatIBD, flag errors, monitor accuracy and ensure consistent quality over time.
Help Shape the Future of IBD Care
If you share our vision for making IBD care more accessible and consistent, please share ChatIBD with your colleagues. With your feedback and support, we hope to build a sustainable resource for the IBD community.
If you would like to sponsor this project, let us know too!